Melittin-incorporated nanomedicines for enhanced cancer immunotherapy
- 13 September 2024
- journal article
- review article
- Published by Elsevier in Journal of Controlled Release
- Vol. 375, 285-299
Abstract
No abstract availableKeywords
Funding Information
- National Natural Science Foundation of China (82473365, U23A20591, 52273158, 52203201)
- Youth Innovation Promotion Association of the Chinese Academy of Sciences
- Jilin Provincial Scientific and Technological Development Program (20240101002JJ, 20220204011YY)
This publication has 100 references indexed in Scilit:
- Immunomodulatory activities and biomedical applications of melittin and its recent advancesArchiv der Pharmazie, 2024
- Development of a Cancer Vaccine Using In Vivo Click‐Chemistry‐Mediated Active Lymph Node Accumulation for Improved ImmunotherapyAdvanced Materials, 2021
- Proapoptotic Peptide Brush Polymer Nanoparticles via Photoinitiated Polymerization‐Induced Self‐AssemblyAngewandte Chemie International Edition, 2020
- Application of bee venom and its main constituent melittin for cancer treatmentCancer Chemotherapy and Pharmacology, 2016
- Tumor-derived factors modulating dendritic cell functionCancer Immunology, Immunotherapy, 2016
- Combined Tumor Cell-Based Vaccination and Interleukin-12 Gene Therapy Polarizes the Tumor Microenvironment in MiceArchivum Immunologiae et Therapiae Experimentalis, 2015
- A novel melittin-MhIL-2 fusion protein inhibits the growth of human ovarian cancer SKOV3 cells in vitro and in vivo tumor growthCancer Immunology, Immunotherapy, 2013
- NMR studies on the monomer–tetramer transition of melittin in an aqueous solution at high and low temperaturesEuropean Biophysics Journal, 2012
- Cytolytic peptide nanoparticles (‘NanoBees’) for cancer therapyWIREs Nanomedicine and Nanobiotechnology, 2011
- Melittin: a Membrane-active Peptide with Diverse FunctionsBioscience Reports, 2007